11 studies were found.

1.		Recruiting	Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small-Cell Lung
2.		No longer recruiting	Phase 1-2a Dose-Ranging Study of TLK286 in Combination with Docetaxel in Platinum-Resistant Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small-Cell Lung
3.		No longer recruiting	Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer Condition: Carcinoma, Non-Small-Cell Lung
4.		No longer recruiting	Phase 2 Study of TLK286 in Metastatic Breast Cancer Condition: Breast Neoplasms
5.		No longer recruiting	Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer Condition: Ovarian Neoplasms
6.		Recruiting	Study of TLK199 HCl Liposomes for Injection in Myelodysplastic Syndrome Condition: Myelodysplastic Syndromes
7.		Recruiting	Study of TLK286 vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Condition: Non Small Cell Lung Carcinoma
8.		Recruiting	TLK286 (Telcyta) in Combination with Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Condition: Non-small cell lung cancer
9.		Recruiting	TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer Condition: Ovarian Neoplasms
10.		No longer recruiting	TLK286 in Combination with Doxil in Platinum Refractory or Resistant Ovarian Cancer Condition: Ovarian Neoplasms
11.		No longer recruiting	TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer Condition: Ovarian Neoplasms